Session XIII: BTKi as a Target

Moderator(s)

• 

  Richard Furman, MD

  NewYork Presbyterian Hospital, Weill Cornell Medicine
  New York, New York, United States

Presenter(s)

• 

  John Allan, MD

  Medicine
  Weill Cornell Medicine
  New York, New York, United States
• 

  Nicole Lamanna, MD

  Columbia University Medical Center/New York Presbyterian
  New York, New York, United States
• 

  Susan O’Brien, MD

  University of California Irvine
  Laguna Beach, California, United States

Talks in this session are supported by educational grants from AstraZeneca Pharmaceuticals , Beigene, Inc, USA and Pharmacyclics, an Abbvie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs, LLC.

Presentations:

• 7:30 AM - 7:35 AM ET

  Welcome and Introduction: Chronic Lymphocytic Leukemia Session
• 7:35 AM - 7:40 AM ET

  Pre-Session Audience Survey
• 7:40 AM - 8:00 AM ET

  Ibrutinib and CAPTIVATE Data Updates
  

  Speaker: John N. Allan, MD – Weill Cornell Medicine
• 8:00 AM - 8:20 AM ET

  Acalabrutinib Data Updates
  

  Speaker: Richard R. Furman, MD – NewYork Presbyterian Hospital, Weill Cornell Medicine
• 8:20 AM - 8:40 AM ET

  Zanubrutinib Data Updates
  

  Speaker: Susan O’Brien, MD – University of California Irvine
• 8:40 AM - 9:00 AM ET

  Pirtobrutinib: The New Kid on the Block
  

  Speaker: Nicole Lamanna, MD – Columbia University Medical Center/New York Presbyterian
• 9:00 AM - 9:15 AM ET

  Panel Discussion: BTKi: Compare and Contrast Efficacy and Toxicity and Post-Session Audience Survey
  

  Moderator: Richard R. Furman, MD – NewYork Presbyterian Hospital, Weill Cornell Medicine

  Panelist: John N. Allan, MD – Weill Cornell Medicine

  Panelist: Nicole Lamanna, MD – Columbia University Medical Center/New York Presbyterian

  Panelist: Susan O’Brien, MD – University of California Irvine